Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics director Paul B. Manning received a grant of stock options as compensation. He was awarded options to buy 2,199 shares of common stock at an exercise price of $10.30 per share. The award replaces normal quarterly cash payments and is fully vested at the time of grant, leaving him with 2,199 derivative securities after this transaction.
Candel Therapeutics director Joseph C. Papa received a new stock option award as part of his board compensation. The grant covers 1,331 options to buy common stock at an exercise price of $10.30 per share.
The award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant, so Papa can exercise all 1,331 options any time until their expiration if he chooses.
Candel Therapeutics director Nicoletta Loggia received a grant of stock options as compensation. The award covers 381 options to buy Candel common stock at an exercise price of $10.30 per share, expiring on June 30, 2036. According to the disclosure, this award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant. Following the grant, Loggia holds 381 stock options directly.
Candel Therapeutics, Inc. director Radhakrishnan Maha received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The option is subject to time-based vesting. All 32,000 underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the company’s next annual stockholder meeting, with vesting ending if the director leaves the board unless the board decides otherwise.
Candel Therapeutics director Nicoletta Loggia received a grant of stock options to buy 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this grant, she holds options covering 32,000 shares.
The award is subject to time-based vesting. The options vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting stopping if she leaves the board unless the board decides otherwise.
Candel Therapeutics director Joseph C. Papa received a grant of stock options, giving him the right to buy 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting. All 32,000 underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the next annual meeting of stockholders, as long as he continues serving on the board. Following this grant, he holds 32,000 stock options directly.
Candel Therapeutics director Edward J. Benz Jr. received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting, becoming exercisable on the earlier of June 23, 2027 or the next Annual Meeting of Stockholders, as long as he continues serving on the board unless the board decides otherwise. Following this grant, he holds 32,000 stock options directly.
Candel Therapeutics director Christopher Martell received a grant of stock options for 32,000 shares of Common Stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting and will vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting ceasing if he leaves the board unless the board decides otherwise. After this grant, he holds 32,000 options directly.